BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter study

EJC Skin Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles